A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
Top Cited Papers
- 1 March 2011
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (3), 211-214
- https://doi.org/10.1016/s1470-2045(10)70275-8
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urotheliumCancer Treatment Reviews, 2008
- Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendationsAnnals of Oncology, 2007
- Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladderCancer, 2006
- Relationship Between Cisplatin Administration and the Development of OtotoxicityJournal of Clinical Oncology, 2006
- Overview of bladder cancer trials in the European Organization for Research and TreatmentCancer, 2003
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of TherapyJournal of Clinical Oncology, 1999